최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기한국호스피스·완화의료학회지 = Korean journal of hospice and palliative care, v.16 no.4, 2013년, pp.205 - 215
이혜란 (인제대학교 일산백병원 혈액종양내과)
Most terminally ill cancer patients experience various physical and psychological symptoms during their illness. In addition to pain, they commonly suffer from fatigue, anorexia-cachexia syndrome, nausea, vomiting and dyspnea. In this paper, I reviewed some of the common non-pain symptoms in termina...
핵심어 | 질문 | 논문에서 추출한 답변 |
---|---|---|
피로감은 어떤 특징을 갖고 있는가? | 암 관련 피로란 암환자들을 괴롭히고, 지속적이며 신체적, 감정적, 인지적 피곤함과 소진감의 주관적 증상이다. 이 증상은 말기암환자들이 가장 흔히 호소하는 주소이며 최근의 활동과 관련없이 휴식으로 호전되지 않는 에너지의 고갈로, 환자들은 많은 잠으로 보충하려는 경향이 있기도하다. 또한, 환자들은 이 자각 증상에 대해 피로감으로 느끼지 못하고 일상 생활의 활동을 끝마치기가 힘들다. | |
말기 암에서 흔히 보이는 10가지 증상은 무엇인가? | 이제는 양질의 완화치료가 암환자의 표준치료로 정착하고 있고, 완화치료의 궁극적 목표는 증상의 경감이다(1). 말기 암에서 흔히 보이는 10가지 증상으로는 통증, 피로감, 쇠약감, 식욕부진, 기력부족(lack of energy), 구강건조, 변비, 조기포만감, 호흡곤란, 체중감소이다(2). 이 증상들 중 통증이 말기암환자의 삶의 질을 떨어뜨리는데 가장 큰 역할을 하지만, 다른 신체적 증상 또한 통증 못지 않게 말기암환자의 삶의 질에 큰 영향을 미친다. | |
암환자를 가장 괴롭히는 고통 1, 2위는 무엇인가? | 이 증상들 중 통증이 말기암환자의 삶의 질을 떨어뜨리는데 가장 큰 역할을 하지만, 다른 신체적 증상 또한 통증 못지 않게 말기암환자의 삶의 질에 큰 영향을 미친다. 어떤 보고에 의하면 암환자를 가장 괴롭히는 고통 1, 2위로 피로감, 식욕부진을 꼽았고, 이들 증상은 실제로 95% 이상의 말기암환자에서 발생되는 것으로 조사되었다(2). 암환자에서 이러한 증상은 대부분 비특이적이고 주관적인 증상이라 이를 객관적으로 평가하여 치료하기란 쉽지 않으며, 특히 말기암환자의 경우는 더욱 더 그러하다(3). |
Ross DD, Alexander CS. Management of common symptoms in terminally ill patients: Part I. Fatigue, anorexia, cachexia, nausea and vomiting. Am Fam Physician 2001;64:807-14.
Tsai JS, Wu CH, Chiu TY, Hu WY, Chen CY. Symptom patterns of advanced cancer patients in a palliative care unit. Palliat Med 2006;20:617-22.
Von Roenn JH, Paice JA. Control of common, non-pain cancer symptoms. Semin Oncol 2005;32:200-10.
Shoemaker LK, Eastfan B, Induru R, Walsh TD. Symptom management: an important part of cancer care. Cleve Clin J Med 2011;78:25-34.
Kim Y. Symptom management for cancer patients. Korean J Hosp Palliat Care 2012;15:61-7.
Hwang SS, Chang VT, Cogswell J, Kasimis BS. Clinical relevance of fatigue levels in cancer patients at a Veterans Administration Medical Center. Cancer 2002;94:2481-9.
Ryan JL, Carroll JK, Ryan EP, Mustian KM, Fiscella K, Morrow GR. Mechanism of cancer-related fatigue. Oncologist 2007;12 Suppl 1:22-34.
Barsevick A, Frost M, Zwinderman A, Hall P, Halyard M; GENEQOL Consortium. I'm so tired: biological and genetic mechanisms of cancer-related fatigue. Qual Life Res 2010;19:1419-27.
National Comprehensive Cancer Network. NCCN practice guidelines [Internet]. Version 1. Fort Washington, PA: National Comprehensive Cancer Network; c2013. 2013 for Cancer-related fatigue [cited 2013 Oct 19]. Available from: http://www.nccn.org/professionals/physician_gls/PDF/fatigue.pdf.
Yun YH, Wang XS, Lee JS, Roh JW, Lee CG, Lee WS, et al. Validation study of the korean version of the brief fatigue inventory. J Pain Symptom Manage 2005;29:165-72.
Kwak SM, Choi YS, Yoon HM, Kim DG, Song SH, Lee YJ, et al. The relationship between interleukin-6, tumor necrosis factor- ${\alpha}$ , and fatigue in terminally ill cancer patients. Palliat Med 2012;26:275-82.
Crews DJ, Landers DM. A meta-analytic review of aerobic fitness and reactivity to psychosocial stressors. Med Sci Sports Exerc 1987;19(5 Suppl):S114-20.
DeWys WD. Weight loss and nutritional abnormalities in cancer patients: incidence, severity and significance. Clin Oncol 1986;5:251-61.
Tisdale MJ. Cancer anorexia and cachexia. Nutrition 2001;17:438-42.
Nicolini A, Ferrari P, Masoni MC, Fini M, Pagani S, Giampietro O, et al. Malnutrition, anorexia and cachexia in cancer patients: A mini-review on pathogenesis and treatment. Biomed Pharmarcother 2013;67:807-17.
National Comprehensive Cancer Network. NCCN practice guidelines [Internet]. Version 2. Fort Washington, PA: National Comprehensive Cancer Network; c2013. 2013 for Palliative care: anorexia/cachexia [cited 2013 Oct 19]. Available from: http://www.nccn.org/professionals/physician_gls/PDF/palliativecare.pdf.
Loprinzi CL, Michalak JC, Schaid DJ, Mailliard JA, Athmann LM, Goldberg RM, et al. Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. J Clin Oncol 1993;11:762-7.
Nelson K, Walsh D, Deeter P, Sheehan F. A phase II study of delta-9-tetrahydrocannabinol for appetite stimulation in cancerassociated anorexia. J Palliat Care 1994;10:14-8.
Jatoi A, Windschitl HE, Loprinzi CL, Sloan JA, Dakhil SR Milliard JA, et al. Dronabinol versus megestro acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol 2002;20:567-73.
Mercadante S, Fulfaro F, Casuccio A. The use of corticosteroids in home palliative care. Support Care Cancer 2001;9:386-9.
Chlebowski RT, Herrold J, Ali I, Oktay E, Chlebowski JS, Ponse AT, et al. Influence of nandrolone decanoate on weight loss in advanced non-small cell lung cancer. Cancer 1986;58:183-6.
Tchekmedyian S, Thropay J, von Roenn J, Ottery F. Patients with aerodigestive tract cancer and pre-existing weight loss: performance status, quality of life, and laboratory parameters with oxandrolone use. IJROBP 2002;54(2 Suppl):311-2.
Bruera E, Strasser F, Palmer JL, Willey J, Calder K, Amyotte G, et al. Effect of fish oil on appetite and other symptoms in patients with advanced cancer and anorexia/cachexia: a double-blind, placebo-controlled study. J Clin Oncol 2003;21:129-34.
Stephenson J, Davies A. An assessment of aetiology-based guidelines for the management of nausea and vomiting in patients with advanced cancer. Support Care Cancer 2006;14:348-53.
National Comprehensive Cancer Network. NCCN practice guidelines [Internet]. Version 2. Fort Washington, PA: National Comprehensive Cancer Network; c2013. 2013 for Palliative care: nausea/vomiting [cited 2013 Oct 19]. Available from: http://www.nccn.org/professionals/physician_gls/PDF/palliativecare.pdf.
Escalante CP, Martin CG, Elting LS, Price KJ, Manzullo EF, Weiser MA, et al. Identifying risk factors for imminent death in cancer patients with acute dyspnea. J Pain Symptom Manage 2000;20:318-25.
National Comprehensive Cancer Network. NCCN practice guidelines [Internet]. Version 2. Fort Washington, PA: National Comprehensive Cancer Network; c2013. 2013 for Palliative care: dyspnea [cited 2013 Oct 19]. Available from: http://www.nccn.org/professionals/physician_gls/PDF/palliativecare.pdf.
Thomas JR, von Gunten CF. Clinical management of dyspnea. Lancet Oncol 2002;3:223-8.
Thomas JR, von Gunten CF. Management of dyspnea. J Support Oncol 2003;1:23-32.
Bruera E, MacEachern T, Ripamonti C, Hanson J. Subcutaneous morphine for dyspnea in cancer patients. Ann Intern Med 1993;119:906-7.
Clemens KE, Quednau I, Klaschik E. Use of oxygen and opioids in the palliation of dyspnoea in hypoxic and non-hypoxic palliative care patients: a prospective study. Support Care Cancer 2009;17:367-77.
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
오픈액세스 학술지에 출판된 논문
※ AI-Helper는 부적절한 답변을 할 수 있습니다.